
    
      The investigational IOL will be found to be safe and effective with respect to visual acuity,
      color vision, contrast sensitivity and complications and will be similar to results for the
      ZA9003 control eyes. Complication rates and adverse event rates will be within the FDA grid
      for posterior chamber IOLs.
    
  